1 Best JD,Jenkins AJ.Novel agents for managing dyslipidaemia.Expert Opin Investing Drugs,2001,10:1901-1911. 2 Williams D,Feely J.Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.Clin Pharmacokinet,2002,41:343-370. 3 Consolo F,Ditommass G,Arrgo F,Trifiro A.Rapid modification of the blood lipid and lipoprotein picture by Co A in human.Boll Soc Ital Biol Sper,1975,51:1920-1926. 4 Consolo F,Ditommass G,Arrgo F,et al.Effects of CoA on modification fo the lipemic picture subsequent to dietary lipid loading.Boll Soc Ital Biol Sper,1975,51:1931-1936. 5 Stein EA.Managing dyslipidemia in the high-risk patient.Am J Cariol,2002,89:50-57. 6 Gaddi A,Descovich GC,Noseda G,et al.Controlled evaluation of Pantethine,a natural hypolipidemic compound,in patients with different forms of hyperlipoproteinemia.Atherosclerosis,1984,50:73-83.